Small molecules that disrupt RAD54-BLM interaction hamper tumor proliferation in colon cancer chemoresistance models
Journal of Clinical Investigation · 2024
DOI: 10.1172/jci161941 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Ekjot Kaur und 14 weiteren Autor:innen. Beteiligte Einrichtung: Biotechnology Research Innovation Council-National Institute of Immunology (BRIC-NII), New Delhi, India. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Colonic Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Immunology, Department of Biotechnology, India, Board of Research in Nuclear Sciences, India.
Abstract (Originalsprache)
RAD54 and BLM helicase play pivotal roles during homologous recombination repair (HRR) to ensure genome maintenance. BLM amino acids (aa 181-212) interact with RAD54 and enhance its chromatin remodeling activity. Functionally, this interaction heightens HRR, leading to a decrease in residual DNA damage in colon cancer cells. This contributes to chemoresistance in colon cancer cells against cisplatin, camptothecin, and oxaliplatin, eventually promoting tumorigenesis in preclinical colon cancer mouse models. ChIP-Seq analysis and validation revealed increased BLM and RAD54 corecruitment on the MRP2 promoter in camptothecin-resistant colon cancer cells, leading to BLM-dependent enhancement of RAD54-mediated chromatin remodeling. We screened the Prestwick small-molecule library, with the intent to revert camptothecin- and oxaliplatin-induced chemoresistance by disrupting the RAD54-BLM interaction. Three FDA/European Medicines Agency-approved candidates were identified that could disrupt this interaction. These drugs bound to RAD54, altered its conformation, and abrogated RAD54-BLM-dependent chromatin remodeling on G5E4 and MRP2 arrays. Notably, the small molecules also reduced HRR efficiency in resistant lines, diminished anchorage-independent growth, and hampered the proliferation of tumors generated using camptothecin- and oxaliplatin-resistant colon cancer cells in both xenograft and syngeneic mouse models in BLM-dependent manner. Therefore, the 3 identified small molecules can serve as possible viable candidates for adjunct therapy in colon cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biotechnology Research Innovation Council-National Institute of Immunology (BRIC-NII), New Delhi, India.
- Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR), Singapore.
- School of Life Sciences, Jawaharlal Nehru University, New Delhi, India.
- Regional Centre for Biotechnology, NCR Biotech Science Cluster, Faridabad, Haryana, India.
- UMR CNRS 7276, INSERM U1262, CRIBL, Université Limoges, Limoges, France.
- Biotechnology Research Innovation Council-National Institute of Biomedical Genomics (BRIC-NIBMG), Kalyani, India.
Förderung
- National Institute of Immunology
- Department of Biotechnology, India
- Board of Research in Nuclear Sciences, India
- Science & Engineering Research Board, India
- J C Bose Fellowship
- Department of Science and Technology, India
- INCa PLBIO PLBIO
- Ligue Contre le Cancer, Foundation ARC
Zitieren
APA
Kaur, E., Agrawal, R., Arun, R., Madhavan, V., Srivastava, V., Kumar, D., Rath, P. P., Kumar, N., Vedagopuram, S., Pandey, N., Priya, S., Legembre, P., Gourinath, S., Bajaj, A., & Sengupta, S. (2024). Small molecules that disrupt RAD54-BLM interaction hamper tumor proliferation in colon cancer chemoresistance models. Journal of Clinical Investigation. https://doi.org/10.1172/jci161941
Vancouver
Kaur E, Agrawal R, Arun R, Madhavan V, Srivastava V, Kumar D, et al. Small molecules that disrupt RAD54-BLM interaction hamper tumor proliferation in colon cancer chemoresistance models. Journal of Clinical Investigation. 2024. doi:10.1172/jci161941
BibTeX
@article{Kaur2024,
author = {Kaur, Ekjot and Agrawal, Ritu and Arun, Rimpy and Madhavan, Vinoth and Srivastava, Vivek and Kumar, Dilip and Rath, Pragyan Parimita and Kumar, Nitin and Vedagopuram, Sreekanth and Pandey, Nishant and Priya, Swati and Legembre, Patrick and Gourinath, Samudrala and Bajaj, Avinash and Sengupta, Sagar},
title = {Small molecules that disrupt RAD54-BLM interaction hamper tumor proliferation in colon cancer chemoresistance models},
journal = {Journal of Clinical Investigation},
year = {2024},
doi = {10.1172/jci161941}
}
EUVIMED